# Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate

Source: https://onco.cc/trials/nct07230509/  
OnCo record `nct07230509` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by Minia University, now recruiting.

## Summary

Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate is a phase 2, randomised interventional study registered as NCT07230509 by Minia University, with a registry enrolment figure of 90 participants, started 2025-12-01 and due to reach its primary completion in 2027-12-01. Interventions recorded: Pancreatic parenchymal injection of N-butyl-2- cyanoacrylate(Histoacryl®)Injection Group.; Standard Pancreaticojejunostomy. Conditions listed: Pancreaticoduodenectomy; Postoperative Pancreatic Fistula; Pancreas Cancer; Periampullary Cancer. Primary outcome: Incidence of postoperative pancreatic fistula. Pancreatic eligibility wording from the registry: "* Patients undergoing pancreaticoduodenectomy for malignant lesions meeting the curative treatment intent in accordance with clinical guidelines". Sites: Egypt. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: NBCA
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07230509
- Phase: 2
- Setting: Efficacy of Pancreatic Parenchymal N-Butyl-2-Cyanoacrylate Injection in Pancreaticojejunostomy After Pancreaticoduodenectomy: A Randomized Controlled Trial
- Sponsor: Minia University
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07230509: https://clinicaltrials.gov/study/NCT07230509

## Connected records

- cancers: [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07230509.json